Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Moodys
Express Scripts
McKinsey
Merck

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 4,160,021

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 4,160,021
Title: Substituted 2H-pyran-2,6(3H)-dione derivatives
Abstract:Substituted 2H-pyran-2,6(3H)-dione derivatives useful in the treatment of allergic conditions are prepared by reaction of 3,5-diacetyl-4,6-dihydroxy-2H-pyran-2-one with an appropriate aniline.
Inventor(s): Snader; Kenneth M. (Hatboro, PA)
Assignee: SmithKline Corporation (Philadelphia, PA)
Application Number:05/885,142
Patent Claims:1. A compound represented by the formula: ##STR5## wherein: R.sub.1 is lower alkoxy oxamoyl, hydroxyoxamoyl, lower alkoxy carbamoyl;

R.sub.2 is lower alkoxy oxamoyl, hydroxyoxamoyl, lower alkoxy carbamoyl, and when R.sub.1 is lower alkoxy carbamoyl, R.sub.2 is also hydrogen, and when R.sub.2 is not hydrogen R.sub.1 and R.sub.2 are the same; and

the lower alkoxy moieties have 1 or 2 carbon atoms, or a mono- or di-alkali metal salt of said compound.

2. A compound according to claim 1 in which R.sub.1 and R.sub.2 are ethoxyoxamoyl.

3. A compound according to claim 1 in which R.sub.1 and R.sub.2 are hydroxyoxamoyl.

4. A compound according to claim 1 in which R.sub.1 and R.sub.2 are ethoxycarbamoyl.

5. A compound according to claim 1 in which R.sub.1 is ethoxycarbamoyl and R.sub.2 is hydrogen.

6. A pharmaceutical composition for inhibiting the symptoms of asthma comprising a nontoxic pharmaceutical carrier or diluent and an amount sufficient to produce said inhibition of a compound represented by the formula: ##STR6## wherein: R.sub.1 is lower alkoxy oxamoyl, hydroxyoxamoyl, lower alkoxy carbamoyl;

R.sub.2 is lower alkoxy oxamoyl, hydroxyoxamoyl, lower alkoxy carbamoyl, and when R.sub.1 is lower alkoxy carbamoyl, R.sub.2 is also hydrogen, and when R.sub.2 is not hydrogen R.sub.1 and R.sub.2 are the same; and

the lower alkoxy moieties have 1 or 2 carbon atoms, or a mono- or di-alkali metal salt of said compound.

7. A pharmaceutical composition according to claim 6 in a form suitable for administration by inhalation.

8. A pharmaceutical composition according to claim 6 comprising a solution or suspension of the active ingredient in sterile water.

9. A pharmaceutical composition according to claim 6 in the form of an aerosol formulation.

10. A pharmaceutical composition according to claim 6 in which the pharmaceutical carrier or diluent is a solid.

11. A pharmaceutical composition according to claim 6 in which R.sub.1 and R.sub.2 are ethoxyoxamoyl.

12. A pharmaceutical composition according to claim 6 in which R.sub.1 and R.sub.2 are hydroxyoxamoyl.

13. A pharmaceutical composition according to claim 6 in which R.sub.1 and R.sub.2 are ethoxycarbamoyl.

14. A pharamceutical composition according to claim 6 in which R.sub.1 is ethoxycarbamoyl and R.sub.2 is hydrogen.

15. A pharmaceutical composition according to claim 6 in dosage unit form and in which the active ingredient is in an amount of from about 0.5 to about 500 mg. per dosage unit.

16. A method of inhibiting the symptoms of asthma which comprises administering to an animal in need of said inhibition a therapeutically effective amount for producing said inhibition of a compound represented by the formula: ##STR7## wherein: R.sub.1 is lower alkoxy oxamoyl, hydroxyoxamoyl, lower alkoxy carbamoyl;

R.sub.2 is lower alkoxy oxamoyl, hydroxyoxamoyl, lower alkoxy carbamoyl, and when R.sub.1 is lower alkoxy carbamoyl, R.sub.2 is also hydrogen, and when R.sub.2 is not hydrogen R.sub.1 and R.sub.2 are the same; and

the lower alkoxy moieties have 1 or 2 carbon atoms, or a mono-or di-alkali metal salt of said compound.

17. The method according to claim 16 in which the active ingredient is administered in a daily dosage regimen of from about 0.5 mg. to about 2000 mg.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Harvard Business School
AstraZeneca
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.